Cargando…
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
BACKGROUND: Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. AIM: To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglut...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617813/ https://www.ncbi.nlm.nih.gov/pubmed/31246368 http://dx.doi.org/10.1111/apt.15316 |
_version_ | 1783433776522592256 |
---|---|
author | Newsome, Philip Francque, Sven Harrison, Stephen Ratziu, Vlad Van Gaal, Luc Calanna, Salvatore Hansen, Morten Linder, Martin Sanyal, Arun |
author_facet | Newsome, Philip Francque, Sven Harrison, Stephen Ratziu, Vlad Van Gaal, Luc Calanna, Salvatore Hansen, Morten Linder, Martin Sanyal, Arun |
author_sort | Newsome, Philip |
collection | PubMed |
description | BACKGROUND: Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. AIM: To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglutide, on alanine aminotransferase (ALT) and high‐sensitivity C‐reactive protein (hsCRP) in subjects at risk of NAFLD. METHODS: Data from a 104‐week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52‐week weight management trial (semaglutide 0.05‐0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight. RESULTS: Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end‐of‐treatment ALT reductions were 6%‐21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%‐43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%‐46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end‐of‐treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change. CONCLUSIONS: Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes. |
format | Online Article Text |
id | pubmed-6617813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66178132019-07-22 Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity Newsome, Philip Francque, Sven Harrison, Stephen Ratziu, Vlad Van Gaal, Luc Calanna, Salvatore Hansen, Morten Linder, Martin Sanyal, Arun Aliment Pharmacol Ther Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity BACKGROUND: Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. AIM: To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglutide, on alanine aminotransferase (ALT) and high‐sensitivity C‐reactive protein (hsCRP) in subjects at risk of NAFLD. METHODS: Data from a 104‐week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52‐week weight management trial (semaglutide 0.05‐0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight. RESULTS: Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end‐of‐treatment ALT reductions were 6%‐21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%‐43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%‐46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end‐of‐treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change. CONCLUSIONS: Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes. John Wiley and Sons Inc. 2019-06-10 2019-07 /pmc/articles/PMC6617813/ /pubmed/31246368 http://dx.doi.org/10.1111/apt.15316 Text en © 2019 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity Newsome, Philip Francque, Sven Harrison, Stephen Ratziu, Vlad Van Gaal, Luc Calanna, Salvatore Hansen, Morten Linder, Martin Sanyal, Arun Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
title | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
title_full | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
title_fullStr | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
title_full_unstemmed | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
title_short | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
title_sort | effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity |
topic | Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617813/ https://www.ncbi.nlm.nih.gov/pubmed/31246368 http://dx.doi.org/10.1111/apt.15316 |
work_keys_str_mv | AT newsomephilip effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT francquesven effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT harrisonstephen effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT ratziuvlad effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT vangaalluc effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT calannasalvatore effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT hansenmorten effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT lindermartin effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity AT sanyalarun effectofsemaglutideonliverenzymesandmarkersofinflammationinsubjectswithtype2diabetesandorobesity |